第五章 討論
第三節 結論
在體外試驗中，五苓散萃取液有抑制草酸鈣結晶形成的效用，是經 由抑制草酸鈣結晶核心的形成以及抑制結晶顆粒間相互的聚集。在動 物試驗中，五苓散能有效抑制鼠腎小管中草酸鈣結晶的沉積。因此，
五苓散有潛在的能力可以預防草酸鈣結石的發生，這結果可由進一步 的臨床應用來證實。
本研究亦建立了良好的實驗平台和動物模式來篩選具抗結石功效 的中草藥，期望為預防尿路結石做出重大的貢獻。
參 考 文 獻
1.Marshall L, Damien M. Urinary stone disease. In: Smith´s general urology（15/e）, Eds Emil AT and Jack WM, McGraw-Hill Co., Inc., United States of America 2000; pp. 291-320.
2.Mani M, Martin IR. Urinary lithiasis: etiology, diagnosis, and medical management. In: Campbell´s Urology（8/e）, Eds Patrick CW, Elsevier Science Publishing Co., Inc., New York 2002; pp.
3229-305.
3.Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States:1976-1994. Kidney Int. 2003;63:1817-23.
4.Barbasa C, Garc´ıaa A, Saavedraa L, Murosb M. Urinary analysis of nephrolithiasis markers. J Chromatogr B. 2002;781:433-55.
5.Lee YH, Huang WC, Tsai JY, Lu CM, Chen WC, Lee MH, Hsu HS, Huang JK, Chang LS. Epidemiological studies on the prevalence of upper urinary calculi in Taiwan. Urol Int. 2002;68:172-7.
6.Uribarri J, Man S, Carroll JH. The first kidney stone. Ann Int Med. 1989;111:1006-9.
7.Ljungghall S, Danielson BG. A prospective study of renal stone recurrences. Br J Urol. 1984;56:122–4.
8.李瀛輝、黃榮慶、陳明村、張心湜：性別與年齡在上尿路結石流行病 學所扮演之角色。中華民國泌尿科醫學會雜誌 1992; 3: 824-30.
9.李瀛輝、張心湜、陳明村、黃榮慶：台灣南部地區尿路結石流行病學 之研究。中華民國泌尿科醫學會雜誌 1994; 5: 1-7.
10.Chandhoke PS. When is medical prophylaxis cost-effective for recurrent calcium stones? J Urol. 2002;168:937-40.
11.Robertson WR. The economics of urinary stone management. In:
Kidney Stones, 8th European Symposium on Urolithiasis, Eds Borghi L, Meschi T, Briganti A, Schianchi T and Novarini A,
Editoriale Bios, Parma, Italy 1999; pp. 169-72.
12.Strohmaier WL, Hormann M. Economic aspect of urolithiasis and metaphylaxis in Germany. In: Urolithiasis, Eds Rodgers AL, Hibbert BE, Hess B, Khan SR and Preminger GM, University of Cape Town, Cape Town 2000; pp. 406-9.
13.單書健、陳子華：古今名醫臨証金鑒‧淋証癃閉卷，中國中醫藥出 版社，北京 1999
14.http://www.zgxl.net/SLJK/ybjb/miniao/linzheng.htm
15.Sonja L, Allen LR. Idiopathic calcium oxalate urolithiasis:
risk factors and conservative treatment. Clin Chim Acta.
2004;345:17–34.
16.Robertson WG, Peacock M. The cause of idiopathic calcium stone disease: hypercalciuria or hyperoxaluria? Nephron 1980;26:105-10.
17.Robertson WG. Mild hyperoxaluria: a critical review and future outlook. In: Kidney Stones, 8th European Symposium on Urolithiasis, Eds Borghi L, Meschi T, Briganti A, Schianchi T and Novarini A, Editoriale Bios, Parma, Italy 1999; pp.
33-42.
18.Coe FL. Hyperuricosuric calcium oxalate nephrolithiasis.
Kidney Int. 1978;13:418-26.
19.Ettinger B. Allopurinol for treatment of uric acid and calcium calculi. In: Pharmacological Treatment of Endocrinopathies, Eds Pak CYC, Karger, Basel 1991; pp. 16-36.
20.Curhan GC. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med. 1993;328:833-8.
21.Wahl C, Hess B. Kidney calculi-is nutrition a trigger or treatment. Rev Ther. 2000;57:138-45.
22.Marangella M, Vitale C, Petrarulo M, Bagnis C, Bruno M, Ramello
A. Renal stones: from metabolic to physicochemical abnormalities. How useful are inhibitors? J Nephrol.
2000;13:S51-60.
23.Bihl G, Meyers A. Recurrent renal stone disease-advances in pathogenesis and clinical management. Lancet. 2001;
358:651-6.
24.Wilson DM. Clinical and laboratory approaches for evaluatione of nephrolithiasis. J Urol. 1989;141:770-4.
25.李瀛輝、陳明村、張心湜：尿路結石，九州圖書文物有限公司，台 北 1980。
26.Chaussy C, Schüller J, Schmiedt E, Brandl H, Jocham D, Liedl B. Extracorporeal shock wave lithotripsy for treatment of urolithiasis. Urol. 1984;23:59-66.
27.孫光煥、于大雄：尿路結石之治療最新發展，九州圖書文物有限公 司，台北 1996;pp.13-67.
28.Khan SR. Interactions between stone-forming calcific crystals and macromolecules. Urol Int. 1997;59:59-71.
29.Bernhard H, Dirk JK. Nucleation, growth, and aggregation of stone-forming crystals. In: Kidney stone: medical and surgical management, Eds Coe FL, Favus MJ, Pak CYC, Parks JH and Preminger GM, Lippincott-Raven Publishers, Philadelphia 1996;
pp. 3-32.
30.Begun FP, Knoll CE, Gottlieb M, Lawson RK. Chronic effects of focused electrohydraulic shock waves on renal function and hypertention. J Urol. 1991;145:635-9.
31.Kishimoto T, Yamamoto K, Sugimoto T, Yoshihara H, Maekawa M.
Side effects of extracorporeal shock-wave exposure in patients treated by extracorporeal shock-wave lithotripsy for upper urinary tract stone. Eur Urol. 1986;12:308-13.
32.Ruml LA, Pearle MS, Pak CYC. Medical therapy, calcium oxalate
urolithiasis. Urol Clin North Am. 1997;24:117-33.
33.Mani M, Martin IR. Urinary lithiasis: etiology, diagnosis, and medical management. In: Campbell´s Urology（8/e）, Eds Patrick CW, Elsevier Science Publishing Co., Inc., New York 2002; pp.
3280-5.
34.Atmani F, Khan SR. Effect of an extract from
Herniaria hirsute
on calcium oxalate crystallisation in vitro. BJU Int.2000;85:621-5.
35.Atmania F
,
Slimania Y, Mimounib M, Aziza M, Hachtb B, Ziyyata A. Effect of aqueous extract fromHerniaria hirsute
L. on experimentally nephrolithiasic rats. J Ethnopharmacol.2004;95:87-93.
36.Joshia VS, Parekha BB, Joshia MJ, Vaidyaba AB. Herbal extracts of
Tribulus terrestris
andBergenia ligulata
inhibit growth of calcium oxalate monohydrate crystals in vitro. J Cryst Growth. 2005;275:1403-08.37.Dasa I, Guptaa SK, Ansaria SA, Pandeyb VN, Rastogi RP. In vitro inhibition and dissolution of calciumoxalate by edible plant
Trianthema monogyna
and pulseMacrotyloma uniflorum
extracts.J Cryst Growth. 2005;273:546-54.
38.譚思濰、陳玉芳、柯毅文、蔡輝彥：二金排石湯對於實驗性動物 膀胱結石之研究。J Chin Med. 2004;15:17-29.
39.Suzuki K, Kawamura K, Tsugawa R. Formation and growth
inhibition of calcium oxalate crystals by Takusha（
Alismatis Rhizoma
）. Scanning Microsc. 1999;13:183-9.40.Yasui T, Fujita K, Sato M, Sugimoto M, Iguchi M, Nomura S, Kohri K. The effect of takusha, a kampo medicine, on renal stone formation and osteopontin expression in a rat urolithiasis model. Urol Res. 1999;27:194-9.
41.Utsunomiya M, Koide T, Yamaguchi S, Yoshioka T, Sonoda T, Sugiyama K. The effect of kanpou medicine on the growth and aggregation of calcium oxalate crystals in vitro. Hinyokika Kiyo. 1991;37:1097-101.
42.Koide T, Yamaguchi S, Utsunomiya M, Yoshioka T, Sugiyama K.
The inhibitory effect of kampou extracts on in vitro calcium oxalate crystallization and in vivo stone formation in an animal model. Int J Urol. 1995;2:81-6.
43.Yoshimura K, Miyake O, Okuyama A, Yoshioka T, Honda M, Yamaguchi S, Koide T. Effect of chorei-to and gorei-san on calcium oxalate crystallization in human urine. Hinyokika Kiyo.
1998;44:13-6.
44.Liu QL, Sato S, Kishikawa T, Matsuzaki H, Yamanaka N.
Effectiveness of a traditional Chinese medicine, Wulingsan, in suppressing the development of nephrocalcinosis induced by a high phosphorus diet in young rats. Med Electron Microsc.
2001;34:103-14.
45.Barros ME, Schor N, Boim MA. Effects of an aqueous extract from
Phyllantus niruri
on calcium oxalate crystallization in vitro.Urol Res. 2003;30:374-9.
46.Nishiura JL, Campos AH, Boim MA, Heilberg IP, Schor N.
Phyllanthus niruri
normalizes elevated urinary calcium levels in calcium stone forming (CSF) patients. Urol Res.2004;32:362-6.
47.馮勇：中醫十大名方-五苓散，中國中醫藥出版社，北京 1998 48.陳汶吉：尿路結石的生物礦化機制探索 博士論文，國立清華大學生
命科學系，新竹 2001; pp. 27-9.
49.Harris SS, Eccleshall R, Gross C, Dawson-Hughes B, Feldman D.
The vitamin D receptor start codon polymorphism (Fok I) and bone mineral density in premenopausal American black and white
women. J Bone Miner Res. 1997;12:1043-8.
50.Nakagawa Y, Abram V, Kezdy FJ, Kaiser ET, Coe FL. Purification and characterization of the principal inhibitor of calcium oxalate monohydrate crystal growth in human urine. J Biol Chem.
1983;258:12594-600.
51.Meyer JL, Thomas Jr. WC. Trace metal-citric acid complexes as inhibitors of calcification and crystal growth. II. Effects of Fe(III), Cr(III) and Al(III) complexes on calcium oxalate crystal growth. J Urol. 1982;128:1376-8.
52.Hess B, Meinhardt U, Zipperle L, Giovanoli R, Jaeger P.
Simultaneous measurements of calcium oxalate crystal
nucleation and aggregation: impact of various modifiers. Urol Res. 1995;21:231-8.
53.Lee YH, Chang LS, Chen MT, Chiang H, Huang JK, Huang WC.
Characterization of ethylene glycol：Induced urolithiasis model in rats. J Urol ROC. 1991;2:518-24.
54.Nelde HJ, Bichler KH, Strohmaier WL, Kriz W. Nephrolithiasis in the kidney of the rat on atherogenic diet and the effect of calcium antagonists(Nifedipine). In: Nephrocalcinosis calcium antagonists and kidney, Eds Bichler KH and Strohmaier WL, Springer-Verlag, Berlin 1988; pp. 113-25.
55.沈明來：試驗設計學 第二版，九州圖書文物有限公司，台北 1999;
pp. 27-62.
56.沈明來：實用無母數統計學與計數資料分析，九州圖書文物有限公 司，台北 1997; pp. 1-214.
57.Grover PK, Ryall RL, Marshall VR. Does Tamm-Horsfall mucoprotein inhibit or promote calcium oxalate
crystallization in human urine? Clin Chim Acta.
1990;190:223-34.
58.Grover PK, Moritz RL, Simpson RJ, Ryall RL. Inhibition of
growth and aggregation of calcium oxalate crystals
in vitro
： A comparison of four human proteins. Eur J Biochem. 1998;253：637-44.
59.Bretherton T, Rodgers A. Crystallization of calcium oxalate in minimally diluted urine. J Cryst Growth. 1998;192:448-55.
60.Schneider HJ, Bothor W, Berg W, Borner RH, Jakob M. A gel model for measuring crystallization inhibitor activities. Urol Int.
1983;38:33-8.
61.http://brc.se.fju.edu.tw/protein/analysis/enzymeac.htm 62.http://www.its.bldrdoc.gov/projects/devglossary/_optical_d
ensity.html
63.Institute of Clinical Acupuncture and Oriental Medicine.
Chinese herbal medicine formulas. Citation from:
http://www.orientalmedicine.edu/Formulas%20that%20Expel%20 Dampness.pdf
64.Kano Y, Takaguchi S, Nohno T, Hiragami F, Kawamura K, Iwama MK, Miyamoto K, Takehara M. Chinese medicine induces neurite outgrowth in PC12 mutant cells incapable of differentiation.
Am J Chin Med. 2002;30:287-95.
65.Chen WC, Shih CC, Lu WA, Li PC, Chen CJ, Hayakawa S, Shimizu K, Chien CT. Combination of Wu Lin San and Shan Zha ameliorates substance P-induced hyperactive bladder via the inhibition of neutrophil NADPH oxidase activity. Neurosci Lett.
2006;402:7-11.
66.Leth PM, Gregersen M. Ethylene glycol poisoning. Forensic Sci Int. 2005;155:179-184.
67.Guo C, McMartin KE. The cytotoxicity of oxalate, metabolite of ethylene glycol, is due to calcium oxalate monohydrate formation. Toxicology. 2005;208:347-55.
68.Khan SR, Byer KJ, Thamilvan S, Hackett RL, McCormack WT, Benson
NA, Vaughn KL, Erdos GW. Crystal-cell interaction and
apoptosis in oxalate-associated injury of renal epithelial cells. J Am Soc Nephrol. 1999;10:S457-63.
69.李士瑋：生命中無法承受的痛－尿路結石，和記圖書出版社，台北 2003; pp.45-114.
70.Halabe A, Shor R, Wong NLM, Sutton RAL. Effect of vitamin D3 on the conversion of ethylene glycol to glycolate and oxalate in ethylene glycol-fed rats. Clin Chim Acta. 2003;330:135-9.
附 錄
A.
B.
C.
附錄一 用偏光顯微鏡觀察(100x)，以半定量的方式分級草酸鈣結晶沉 積：A：mild; B：moderate; C：massive；Scale bar=0.1 mm
附錄二 乙二醇（Ethylene glycol）在人體和動物體中代謝合成草酸的 途徑 [70]
（圖取自於 Halabe et al. Clinica Chimica Acta. 2003;330:136.）
Wu-Ling-San Formula Inhibits the Crystallization of Calcium Oxalate in vitro and in rats
Graduate student：Yu-Cheng Chen Major professor：Sheng-Feng Hsu
Graduate institute of Chinese Medical Science, China Medical University
Urinary stone disease is a common and high-recurrent disease.
There is no ideal medical drug to prevent the recurrence of urinary stone. Therefore, to develop effective medical drugs is a worthwhile issue. The purpose of this study was to investigate the effect of Wu-Ling-San（WLS）on calcium oxalate formation by using crystallization experiments of crystal nucleation, growth, and aggregation in vitro. Then the animal study was followed to investigate the effect of WLS on EG（ethylene glycol）-induced nephrolithiasic rats. The results of crystallization experiments indicated that WLS extract exerted an effect in the inhibition of calcium oxalate crystallization by inhibiting the nucleation and aggregation. The results of animal study revealed WLS could inhibit calcium oxalate crystal deposition effectively in renal tubules of rats fed by EG. Therefore, it may have potential for preventing stone recurrence if further clinical study can be confirmed.
Key word：Urinary stone, Wu-Ling-San formula, Calcium oxalate
謝 辭
當初秉持著要以科學化的方法來證實中醫效用的信念，進而來到中 國醫學研究所學習，想要努力證明中醫並不是怪力亂神或是不科學，而 是數千年來老祖宗寶貴的智慧結晶。現今中國醫學慢慢已經在國外有發 揚光大的趨勢，但在國內仍被少數人視如敝屣，實為痛心，在此希望盡 自己一份棉薄心力來延續和發展中國醫學，期望付予嶄新的面貌。
兩年時間匆匆過去，在研究所的老師和前輩的教導下，獲得了許多 有用的知識和觀念，也對於中醫科學研究開始跨出了第一步，這一步雖 然很辛苦，但是回首起來真的很充實，收穫真的很多。然而兩年所能達 到的成果不多，而今後要走的路還很長遠，仍然希望往後有機會和前輩 及有志者一同努力。
父親十餘年來身體一直不是很好，在今年一月間辭世。自己未能把 此成果親自呈獻給他，心中不免有些遺憾。非常感謝父親二十幾年來辛 苦培育之恩，讓我衣食無虞能夠好好的學習醫學，才能夠達到目前的成 就，您的恩情浩瀚，實是無以回報。也感謝母親辛勞的撫養之恩，誠心 希望您未來的日子能夠健康快樂。也非常謝謝關心我、幫助我的伯伯、
叔叔、姑姑等長輩們。
兩年來，經由許多人的幫助，我才能順利的完成學業，在此由衷感 激你們：感謝陳汶吉教授的用心指導實驗進行和論文寫作，讓我獲益匪 淺；感謝陳悅生教授在論文寫作上的指導；感謝許昇峰教授指導論文寫 作以及在澄清中醫科工作上的協助；感謝賴銘淙老師在病理切片上的詳 細教導；感謝澄清中醫科的所有同仁在這兩年來愉快的相處和協助，讓 我獲得非常寶貴的臨床經驗；感謝秀雯給予多方面的支持與幫助；感謝 寧漪姊的大力幫忙；感謝凱揚、承志兩位學弟實驗上的協助；感謝李佳 霖同學在統計方面的友情指導；感謝蔡輔仁院長實驗室的同仁們在各方 面的協助；感謝所有研究所的老師和同學，讓我擁有美好、充實的兩年 碩士研究生涯。